AD Outcomes Improved With Lebrikizumab and Topical Steroids
The ADhere study compared responses at 16 weeks to the investigational biologic and topical corticosteroids vs topical corticosteroids alone in adults and adolescents with moderate to severe AD.
Medscape Medical News
source https://www.medscape.com/viewarticle/986934?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/986934?src=rss
Comments
Post a Comment